Inaugural Issue of American Association for Cancer Research Journal Cancer Immunology Research Debuts

Cancer Immunology Research, the newest publication of the American Association for Cancer Research (AACR), published its debut issue today.

The journal will publish research articles reporting major advances in all areas of cancer immunology, including basic investigations in host–tumor interactions, developmental therapeutics in model systems, early translational studies in patients, and late-stage clinical trials.

As this journal launches, a new collaboration was also announced today between the AACR and the Cancer Research Institute (CRI). As part of the agreement, Cancer Immunity will publish its final issue this month and Cancer Immunology Research will continue to publish cutting-edge research in cancer immunology.

All content of Cancer Immunity, founded in 2001, will be posted on the Cancer Immunology Research website, allowing readers to access content for both journals in one location. Cancer Immunology Research will devote content to CRI events and activities.

“We are proud to launch this new journal that will further accelerate progress in cancer immunology and immunotherapy and enter into a new partnership with the Cancer Research Institute. By combining the longstanding commitment of CRI to tumor immunology with the breadth and depth of the AACR investment in all aspects of cancer biology, Cancer Immunology Research will serve as a link between immunology and the larger cancer research community,” said Margaret Foti, PhD, MD (h.c.), chief executive officer of the AACR.

Glenn Dranoff, MD, founding editor-in-chief of Cancer Immunology Research and professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School in Boston, will lead this effort, while James P. Allison, PhD, the editor in chief of Cancer Immunity and chair of immunology at The University of Texas MD Anderson Cancer Center, will now serve as a deputy editor of Cancer Immunology Research.

“Cancer immunology, a science that for many decades was largely ignored, is now broadly acknowledged as one of the most promising areas of cancer research, and we look forward to collaborating with AACR in sharing the exciting discoveries and developments in this field with a larger community of oncologists and other cancer specialists,” said Jill O’Donnell-Tormey, PhD, chief executive officer and director of scientific affairs at CRI.

When Cancer Immunity was first published by CRI under the editorship of the late Lloyd J. Old, MD, it was the only journal devoted exclusive to cancer immunology, and disseminated many types of influential scientific content, according to an announcement in the debut issue of Cancer Immunology Research. The recent clinical successes of anti-CTLA-4 and anti-PD-1/L1 monoclonal antibodies, adoptive T-cell therapy, and cancer vaccines suggest the field is now coming to fruition.

“The AACR-CRI collaboration builds upon the vision of Lloyd Old to bring to the benefit of cancer patients the best basic science possible and the most informative clinical trials,” said Dranoff. “Through fostering productive interactions among academic investigators, industry and patient advocates, Cancer Immunology Research will help to accelerate the control and prevention of cancer through effective manipulation of antitumor immunity.”

“The recent rapid expansion of the field and its acceptance by cancer biologists and clinical investigators are evidence of Dr. Old’s foresight, and this new collaboration between CRI and AACR will further the continued development of this powerful strategy for cancer treatment,” said Allison.

Cancer Immunology Research joins the family of AACR journals: Cancer Discovery; Cancer Research; Clinical Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; Molecular Cancer Research; Molecular Cancer Therapeutics; and Cancer Prevention Research.

Follow the AACR on Twitter: @AACR
Follow the AACR on Facebook: https://www.facebook.com/aacr.org

About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s oldest and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 18,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org.